Coast Medical Innovations is reimagining the drainage catheter — a patent-pending device engineered to deliver significantly improved throughput, reduce failure rates, and lower costs for patients, clinicians, and supply chain across the full continuum of care.
Patent-Pending Innovation
Drainage catheters are among the most commonly placed devices in Interventional Radiology — yet the fundamental design has remained largely unchanged for decades. Failure rates remain stubbornly high, occlusion and dislodgement are routine, and the associated costs burden hospitals and patients alike. The Coriolis Catheter is a novel, patent-pending device that directly addresses each of these failures through a breakthrough approach to catheter design — without requiring any change to existing clinical workflows.
Patent Pending — USPTO Application Filed
Our core technology is protected by a pending utility patent covering the novel system architecture, device design, and methods underlying our drainage platform — establishing durable IP exclusivity across all primary clinical applications.
The Drainage Continuum
Clinical Applications
The Coriolis Catheter is designed for the beachhead market of hospital radiology departments — with a phased expansion across all major drainage indications.
The primary beachhead for the Coriolis Catheter. IR departments perform 100–120 drainage procedures per month on average — each one a candidate for improved retention, patency, and throughput with our novel design.
All-purpose drains, nephrostomy, and biliary procedures guided under CT are core Phase 1 applications. The Coriolis Catheter is scaleable across the 8F–12F range used in these high-volume procedures.
Ultrasound-guided centesis and drainage are addressed in Phase 2, with the Coriolis design refined for the unique requirements of these procedures — expanding access across OBLs and ambulatory surgery centers.
Development Roadmap
2023 — 2024
Core platform architecture established. Key patents filed. Founding team assembled from top medical imaging and device engineering programs.
2025
Bench studies and field prototype validation completed. Letters of Intent secured from over 30 top U.S. health systems, institutions, clinicians, and physicians — all prior to design freeze.
2026
Design freeze complete. Manufacturing verification and feasibility underway. FDA registration filing completed for Phase 1 product lines. Initial inventory order placed.
Mid 2027
Full-scale national market launch with complete coverage. Initial deployments across hospital radiology departments, OBLs, and ASCs. International expansion planning underway.
The Opportunity
"The drainage catheter market is large, underserved, and desperate for a better solution. Every competitor uses the same failed design."
Why Invest
Coast Medical Innovations offers a rare combination of defensible IP, a large and underserved market, and a leadership team with deep domain expertise in the exact market we are entering.
Every current competitor uses the same fundamental pigtail design that is widely acknowledged to fail. The Coriolis Catheter is the first novel drainage device to address all three primary failure modes — simultaneously.
A pending utility patent covers the novel architecture, device design, and clinical methods of the Coriolis platform — establishing durable exclusivity across all primary drainage applications and future product extensions.
The leadership team previously grew non-differentiated products in this identical market from $7M to $20M+ in under five years, with distribution established across 46 countries — now returning with a true technological advantage.
The drainage catheter market is large, recurring, and growing. Hospitals are actively seeking cost-saving solutions — and the Coriolis Catheter delivers estimated savings of $360,000–$500,000 per hospital per year.
Phase 1 and Phase 2 product launches are FDA Class I Exempt, eliminating premarket submission requirements and enabling a fast, low-risk path to market. Groundwork and documentation for FDA Class II products has already been completed.
Initial investment targeted to be fully returned through quarterly distributions by end of 2029, with the company projecting profitability in 2027. Five-year projected ROI of 290% without requiring an exit event.
Get In Touch
Whether you're an accredited investor, a healthcare system leader, or a potential clinical partner — we'd welcome a confidential conversation about what we're building.
Headquarters
Ponte Vedra, Florida
Investor Relations
investors@coastcmi.com
Clinical Partnerships
clinical@coastcmi.com